Article

Access to the text (HTML) Access to the text (HTML)
PDF Access to the PDF text
Advertising


Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates



Journal of the American Academy of Dermatology
Volume 48, n° 4
pages 569-577 (avril 2003)
Doi : 10.1067/mjd.2003.174
Fluocinolone acetonide 0.01% in peanut oil: Therapy for childhood atopic dermatitis, even in patients who are peanut sensitive
 

Amy S. Paller, MDa,b, Sai Nimmagadda, MDa, Lawrence Schachner, MDc, Susan B. Mallory, MDd, Teri Kahn, MDe, Isaac Willis, MDf, Lawrence F. Eichenfield, MDg
Chicago, Illinois; Miami, Florida; St Louis, Missouri; Cleveland, Ohio; Atlanta, Georgia; and San Diego, California 
From the Departments of Pediatricsa and Dermatology,b Children's Memorial Hospital, Northwestern University Medical Center; Departments of Dermatology and Pediatrics, University of Miami Medical Centerc; Departments of Medicine (Dermatology) and Pediatrics, Washington Universityd; Departments of Dermatology and Pediatrics, Cleveland Clinic Foundatione; Department of Dermatology, Morehouse School of Medicinef; and Departments of Pediatrics and Dermatology, San Diego Children's Hospital, University of California, San Diego.g 

Abstract

Background: Fluocinolone acetonide 0.01% in a blend of refined peanut and mineral oils has been used as treatment for scalp psoriasis for several years, but only more recently for atopic dermatitis. Objective: We sought to study the effectiveness for atopic dermatitis, potential for adrenal axis suppression, and safety of the fluocinolone acetonide 0.01% in oil in children with atopic dermatitis, including children with atopic dermatitis and peanut allergic sensitivity. Methods: Three separate studies were performed in children aged 2 to 12 years with atopic dermatitis: multicenter double-blind, randomized, and vehicle-controlled trial; cortisol stimulation testing; and prick testing, patch testing, and monitored medication use in children with peanut allergic sensitivity. Results: Improvement of ≥50% was demonstrated within 2 weeks in 81% to 87% of 81 patients treated with active medication versus 39% of 45 children treated with vehicle oil alone. No adrenal suppression occurred after 4 weeks of therapy in 32 patients. None of 9 patients who were peanut sensitive reacted to either the full formulation or vehicle in prick or patch testing; 20 children who were peanut sensitive showed no allergic reactions after application of the medication. Conclusion: Fluocinolone 0.01% in peanut oil is an effective alternative to the use of topical corticosteroid agents in ointment, cream, and lotion forms in children. No evidence of adrenal suppression or adverse local effects were demonstrated in these studies. The medication was well tolerated in patients with peanut allergic sensitivity. (J Am Acad Dermatol 2003;48:569-77.)

The full text of this article is available in PDF format.

 Supported by Hill Dermaceuticals Inc.
 Disclosure: Drs Paller, Kahn, and Eichenfield are consultants to Hill Dermaceuticals Inc, Fujisawa Healthcare Inc, and Novartis. Dr Kahn is also a consultant for Ortho. Dr Mallory is a consultant for Procter and Gamble.
 Reprint requests: Amy S. Paller, MD, Division of Dermatology No. 107, Children's Memorial Hospital, 2300 Children's Plaza, Chicago, IL 60614. E-mail: apaller@northwestern.edu.
 0190-9622/2003/$30.00 + 0



© 2003  American Academy of Dermatology, Inc. Published by Elsevier Masson SAS@@#104157@@
EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Close
Article Outline